Publicação científica trimestral do CREMERJ - volume 2 - número 2 - 2023

23 Med. Ciên. e Arte , Rio de Janeiro, v.2, n.2, p.13-24, abr-jun 2023 Doença do Refluxo Gastroesofágico Luiz J. Abrahão Junior 7. Moraes-Filho JP, Navarro-Rodriguez T, Barbuti R, et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq Gastroenterol 2010;47(1):99-115, doi:S0004-28032010000100017 [pii] 8. Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology 2016, doi:10.1053/j. gastro.2016.02.012 9. Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut 2023, doi:10.1136/gutjnl-2023-330616 10. Khoury RM, Camacho-Lobato L, Katz PO, et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999;94(8):2069- 73, doi:10.1111/j.1572-0241.1999.01279.x 11. Farup PG, Weberg R, Berstad A, et al. Low-dose antacids versus 400 mg cimetidine twice daily for reflux oesophagitis. A comparative, placebo-controlled, multicentre study. Scand J Gastroenterol 1990;25(3):315-20. 12. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989;24(4):401-6, doi:10.3109/00365528909093066 13. McCallum RW, Fink SM, Winnan GR, et al. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984;79(3):165-72. 14. Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983;30(3):96-8 15. Maton PN. Profile and assessment of GERD pharmacotherapy. Cleve Clin J Med 2003;70 Suppl 5(S51-70, doi:10.3949/ccjm.70.suppl_5.s51 16. Masci E, Testoni PA, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985;11(10):687-92. 17. Lowe RC, Wolfe MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2004;50(3):227-37. 18. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990;19(3):683-712. 19. Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USAMerck Gastroesophageal Reflux Disease Study Group. Arch InternMed 1991;151(12):2394-400. 20. Tytgat GN, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990;99(3):629-34, doi:10.1016/0016-5085(90)90947-y 21. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. N Engl J Med 1990;323(24):1672-80, doi:10.1056/NEJM199012133232405 22. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1(9-14, doi:10.1111/j.1365-2036.1995.tb00778.x 23. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997;11 Suppl B(66B-73B. 24. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001;23(7):998-1017, doi:10.1016/ s0149-2918(01)80087-4 25. Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12(12):1231-4, doi:10.1046/j.1365- 2036.1998.00419.x